TY - JOUR AB - The steadily increasing incidence of malignant melanoma (MM) and its aggressive behaviour makes this tumour an attractive cancer research topic. The tumour microenvironment is being increasingly recognised as a key factor in cancer biology, with an impact on proliferation, invasion, angiogenesis and metastatic spread, as well as acquired therapy resistance. Multiple bioactive molecules playing cooperative roles promote the chronic inflammatory milieu in tumours, making inflammation a hallmark of cancer. This specific inflammatory setting is evident in the affected tissue. However, certain mediators can leak into the systemic circulation and affect the whole organism. The present study analysed the complex inflammatory response in the sera of patients with MM of various stages. Multiplexed proteomic analysis (Luminex Corporation) of 31 serum proteins was employed. These targets were observed in immunohistochemical profiles of primary tumours from the same patients. Furthermore, these proteins were analysed in MM cell lines and the principal cell population of the melanoma microenvironment, cancer‑associated fibroblasts. Growth factors such as hepatocyte growth factor, granulocyte‑colony stimulating factor and vascular endothelial growth factor, chemokines RANTES and interleukin (IL)‑8, and cytokines IL‑6, interferon‑α and IL‑1 receptor antagonist significantly differed in these patients compared with the healthy controls. Taken together, the results presented here depict the inflammatory landscape that is altered in melanoma patients, and highlight potentially relevant targets for therapy improvement. AD - Department of Dermatovenereology, 1st Faculty of Medicine and General University Hospital, Charles University, Prague 128 00, Czech Republic Institute of Anatomy, 1st Faculty of Medicine, Charles University, Prague 128 00, Czech Republic Laboratory of Applied Proteome Analyses and Research Centre PIGMOD, Institute of Animal Physiology and Genetics, Czech Academy of Sciences, Liběchov 277 21, Czech Republic Institute of Pathology, 1st Faculty of Medicine, Charles University, Prague 128 00, Czech Republic AU - Kučera,Jan AU - Strnadová,Karolína AU - Dvořánková,Barbora AU - Lacina,Lukáš AU - Krajsová,Ivana AU - Štork,Jiří AU - Kovářová,Hana AU - Skalníková,Helena,Kupcová AU - Vodička,Petr AU - Motlík,Jan AU - Dundr,Pavel AU - Smetana,Karel AU - Kodet,Ondřej AU - Kučera,Jan AU - Strnadová,Karolína AU - Dvořánková,Barbora AU - Lacina,Lukáš AU - Krajsová,Ivana AU - Štork,Jiří AU - Kovářová,Hana AU - Skalníková,Helena,Kupcová AU - Vodička,Petr AU - Motlík,Jan AU - Dundr,Pavel AU - Smetana,Karel AU - Kodet,Ondřej AU - Kučera,Jan AU - Strnadová,Karolína AU - Dvořánková,Barbora AU - Lacina,Lukáš AU - Krajsová,Ivana AU - Štork,Jiří AU - Kovářová,Hana AU - Skalníková,Helena,Kupcová AU - Vodička,Petr AU - Motlík,Jan AU - Dundr,Pavel AU - Smetana,Karel AU - Kodet,Ondřej DA - 2019/11/01 DO - 10.3892/or.2019.7319 EP - 1804 IS - 5 JO - Oncol Rep KW - melanoma inflammation microenvironment cancer‑​associated fibroblasts interleukin proteomics PY - 2019 SN - 1021-335X 1791-2431 SP - 1793 ST - Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study T2 - Oncology Reports TI - Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study UR - https://doi.org/10.3892/or.2019.7319 VL - 42 ER -